Cardiac actions of central but not peripheral urotensin II are prevented by β-adrenoceptor blockade
Introduction
Urotensin II (UII) is a cyclic peptide isolated initially from the caudal neurosecretory system of the goby fish [3]. Recently, UII isopeptides have been identified in a number of mammals, including mouse, rat, and human [4]. UII is thought to be the endogenous ligand for the orphan GPR14 receptor [2], now termed the UT receptor. The UT receptor is widely expressed, being found in the CNS and vasculature as well as heart and kidney [17], [19]. The wide distribution and the close species homologies of the C-terminal of UII and the UT receptor suggest that UII has important functions in both the brain and periphery.
The systemic cardiovascular actions of UII have been examined in vitro and in vivo, with diverse responses depending on the species and vessel studied. In mammals, UII was first reported to reduce blood pressure in anesthetized rats [12] and cause endothelium-dependent vasodilatation in rat aortic strips [11]. UII was recently shown to have potent vasoconstrictor actions in anesthetized cynomolgus monkeys [2]. In contrast, intravenous administration of UII reduced arterial pressure in conscious rats [9], [14], caused a transient increase followed by a prolonged reduction in arterial pressure in sheep [21] and failed to cause any cardiovascular changes in man [1].
Although UII and its receptor have been localized in the brain, there is little information on the central cardiovascular actions of UII. We found that in conscious sheep, intracerebroventricular (ICV) administration of UII caused prolonged increases in cardiac rate and contractility and cardiac output (CO), together with an increase in mean arterial pressure (MAP) and peripheral vasodilatation in all major vascular beds [21]. These changes were accompanied by large and prolonged increases in circulating levels of epinephrine, but not norepinephrine. Similarly, in conscious rats, ICV administration of UII significantly increased MAP, heart rate (HR) and plasma epinephrine [14].
In view of the finding that central, but not peripheral, UII increased epinephrine release, the current study investigated the extent to which the actions of UII are mediated by β-adrenoreceptors. We examined the effects of β-blockade with propranolol on the responses to ICV and intravenous (IV) administration of UII in conscious sheep. Furthermore, to determine whether an increase in cardiac sympathetic nerve activity (CSNA) also contributed to the cardiac actions of central UII, we examined the effect of UII on directly recorded cardiac sympathetic nerve activity.
Section snippets
Materials and methods
The experiments were performed on 12 adult Merino ewes (35–45 kg), 6 for the hemodynamic studies and 6 for the measurement of CSNA. Experiments were performed on sheep while they were standing in individual metabolism cages. Experiments were approved by the Animal Experimentation Ethics Committee of the Howard Florey Institute following guidelines from the National Health and Medical Research Council of Australia.
Effect of propranolol on the responses to ICV infusion of UII
ICV infusion of UII significantly increased HR (+33 ± 11 beats/min; P = 0.007), dF/dt (+581 ± 83 L/min/s; P < 0.001), Fmax (+8.3 ± 0.9 L/min; P < 0.001) and CO (+2.3 ± 0.4 L/min; P < 0.001) (Fig. 1). These variables remained significantly higher than control for at least 4 h post UII infusion. The cardiac activation was accompanied by a significant increase in TPC (P = 0.017) that lasted for 3.5 h after the end of the UII infusion. In individual vascular beds, UII induced an increase in mesenteric blood flow (P =
Discussion
This study confirms our previous findings that centrally administered UII has potent cardiac actions, causing increases in heart rate, cardiac contractility and cardiac output, which were accompanied by peripheral vasodilatation [21]. The present study extends these findings by investigating the role that the sympathetic nervous system plays in mediating the actions of centrally and peripherally administered UII. The present finding that the cardiac effects of central UII were prevented by
Acknowledgements
The authors are grateful to Craig Thomson and Alan McDonald for excellent technical assistance. This work was funded by National Health and Medical Research Council, Project Grant 232313.
References (22)
- et al.
Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors
FEBS Lett
(1999) - et al.
Congestive heart failure and expression of myocardial urotensin II
Lancet
(2002) - et al.
Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat
Neurosci Lett
(2001) - et al.
Cardiovascular effects of urotensin II in anesthetized and pithed rats
Gen Comp Endocrinol
(1986) - et al.
Cardiovascular effects of urotensin II in different brain areas
Peptides
(2002) - et al.
Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14)
Biochem Biophys Res Commun
(1999) - et al.
Urotensin II: the old kid in town
Trends Endocrinol Metab
(2004) - et al.
No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans
Br J Clin Pharmacol
(2002) - et al.
Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14
Nature
(1999) - et al.
A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts
J Endocrinol
(1969)
Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord
Proc Natl Acad Sci USA
Cited by (25)
Novel insights into the role of urotensin II in cardiovascular disease
2019, Drug Discovery TodayCitation Excerpt :Certain studies that evaluated the effects of UII intracerebroventricular injection reported greater blood pressure increases in spontaneously hypertensive rats when compared with normotensive rats [61]. This means that the peptide can act as a neuromodulator that regulates blood pressure with the contribution of the sympathetic nervous system, mainly through the stimulation of β-adrenoreceptors, in contrast to the systemic activity of UII, which is not mediated by those receptors [62]. The mechanisms underlying the great variability and low efficacy of UII are not entirely known but might be explained by the spare receptor reserve hypothesis.
Intracerebroventricular administration of urotensin II regulates food intake and sympathetic nerve activity in brown adipose tissue
2012, PeptidesCitation Excerpt :Eight weight-matched rats were divided into two groups (n = 4 for each) and were treated with urotensin II (0, 0.01, 0.1, and 1 nmol). The dose of urotensin II was based on our preliminary and previous studies [12,14,15,23]. Test solutions were administered at 1900 h to unrestrained, unanesthetized rats via an i3vt cannula at a rate of 1.0 μl/min for 10 min.
Presence of urotensin-II receptors at the cell nucleus: Specific tissue distribution and hypoxia-induced modulation
2012, International Journal of Biochemistry and Cell BiologyCitation Excerpt :In the CNS, some intracrines were found to act as neurotransmission modulators (Re, 2004). In this regard, it has been demonstrated that UII evokes norepinephrine, dopamine and serotonin release in noradrenergic neurons (Ono et al., 2008) and that intracerebroventricular UII administration produces cardiac system modulation (heart rate, cardiac output) via β-adrenoreceptor stimulation (Hood et al., 2005). These observations, correlated with the regulation by UII and URP of the membrane and nuclear receptors upon hypoxia, bring up the idea that the presence of nuclear UT receptors might be associated to excitatory neurotransmission.
The role of urotensin II in the metabolic syndrome
2008, PeptidesCentral and peripheral cardiovascular, ventilatory, and motor effects of trout urotensin-II in the trout
2008, PeptidesCitation Excerpt :In normotensive and hypertensive unanesthetized rats and in unanesthetized sheep, ICV administration of U-II causes pressor and tachycardic responses through activation of the sympathetic system (for review see [56]) suggesting that in these species the baroreflex response is also impaired. Studies conducted on unanesthetized sheep to test this hypothesis demonstrated that, after ICV infusion of U-II (0.2 nmol/kg for 1 h), the baroreflex response is effectively blunted since no changes occur in the cardiac sympathetic nerve activity in spite of an increase in blood pressure [23]. In trout, comparisons may also be made between the central cardiovascular actions of trout U-II and trout U-I.